GSK N41/2, Samara Oblast

Economic indicators

Net profit (RAS) of GSK N41/2 grew over 2023 52.00 times to 104.00 thousand RUB from 2.00 thousand RUB over 2022, the company informed.

Revenue decreased in the accounting period by 2.96% to 1.51 million RUB from 1.55 million RUB in 2022; cost of goods sold decreased by 8.07% to 1.45 million RUB from 1.57 million RUB; sales profit made up 59.00 thousand RUB compared to sales loss of 22.00 thousand RUB.

Net profit (RAS) of GSK N41/2 dropped in 2022 36.00 times to 2.00 thousand RUB from 72.00 thousand RUB over the same period in 2021, the company informed.

Revenue decreased in the accounting period by 20.49% to 1.55 million RUB from 1.95 million RUB in 2021; cost of goods sold decreased by 15.83% to 1.57 million RUB from 1.87 million RUB; sales loss made up 22.00 thousand RUB compared to sales profit of 82.00 thousand RUB.

Net profit (RAS) of GSK N41/2 made up 72.00 thousand RUB over 2021 compared to net loss of 53.00 thousand RUB over 2020, the company informed.

Revenue increased in the accounting period by 8.32% to 1.95 million RUB from 1.80 million RUB over 2020; sales profit made up 82.00 thousand RUB compared to sales loss of 44.00 thousand RUB.

Net loss (RAS) of GSK N41/2 increased 13.25 times to 53.00 thousand RUB from 4.00 thousand RUB over 2019, the company informed.

Revenue increased in the accounting period by 19.50% to 1.80 million RUB from 1.51 million RUB over 2019; sales loss grew by 46.67% to 44.00 thousand RUB from 30.00 thousand RUB.

Companies in the region

• TANDEM KOMPANI
• MKHTZH
• ADMINISTRATSIYA OCHERSKOGO RAYONA
• FORTUNA
• FINTREYD